A small group of endometrial cancers harbor more than one molecular classifying feature (multiple classifier), and in grade-3 endometrioid carcinoma with mismatch repair deficiency or POLE EDM, hence coexisting TP53 mutation may be a secondary event acquired during tumor progression and was not associated with poorer survival [178]. This evidence concerns the gene TP53 and endometrial cancer.